NCT06602193Phase 2Active not recruiting

Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)

Study sponsor: Denali Therapeutics Inc. · DNLI

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2027-03Estimated

Enrollment · participants50Estimated

Source updated2026-05-27Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-05-27 · 2 fields changed

Primary completion date

Recorded edit

− Previous value

2026-04-30

+ Updated value

2027-03

Recruitment status

Recorded edit

− Previous value

Recruiting

+ Updated value

Active not recruiting

Check registry source